{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:16:57Z","timestamp":1740107817502,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10147-024-02642-9","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:02:19Z","timestamp":1729695739000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5450-8841","authenticated-orcid":false,"given":"Tatsuya","family":"Okuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yanagimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsugu","family":"Sekimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Tobimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Katanuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihito","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"Suppl 1","key":"2642_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G (2019) Cholangiocarcinoma: epidemiology and risk factors. Liver Int 39(Suppl 1):19\u201331","journal-title":"Liver Int"},{"issue":"6","key":"2642_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60(6):1268\u20131289","journal-title":"J Hepatol"},{"issue":"6","key":"2642_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG et al (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149(6):565\u2013574","journal-title":"JAMA Surg"},{"issue":"5","key":"2642_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20(5):663\u2013673","journal-title":"Lancet Oncol"},{"issue":"10372","key":"2642_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M et al (2023) Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet (London, England) 401(10372):195\u2013203","journal-title":"Lancet (London, England)"},{"issue":"4","key":"2642_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.soc.2019.06.002","volume":"28","author":"R El-Diwany","year":"2019","unstructured":"El-Diwany R, Pawlik TM, Ejaz A (2019) Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 28(4):587\u2013599","journal-title":"Surg Oncol Clin N Am"},{"issue":"14","key":"2642_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281","journal-title":"N Engl J Med"},{"issue":"9","key":"2642_CR8","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/cas.12218","volume":"104","author":"C Morizane","year":"2013","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2013) Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci 104(9):1211\u20131216","journal-title":"Cancer Sci"},{"issue":"12","key":"2642_CR9","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30(12):1950\u20131958","journal-title":"Ann Oncol"},{"issue":"1","key":"2642_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S et al (2023) Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). J Hepatobiliary Pancreat Sci 30(1):102\u2013110","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2642_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evid"},{"issue":"10391","key":"2642_CR12","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865","journal-title":"Lancet"},{"issue":"1","key":"2642_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.surg.2020.02.022","volume":"168","author":"NH Nam","year":"2020","unstructured":"Nam NH, Taura K, Kimura Y et al (2020) Extent of liver resection is associated with incomplete liver restoration and splenomegaly a long period after liver resection. Surgery 168(1):40\u201348","journal-title":"Surgery"},{"issue":"8","key":"2642_CR14","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s11605-009-0900-0","volume":"13","author":"Y Murakami","year":"2009","unstructured":"Murakami Y, Uemura K, Sudo T et al (2009) Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg 13(8):1470\u20131479","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"2642_CR15","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/SLA.0b013e3181b0fc8b","volume":"250","author":"Y Murakami","year":"2009","unstructured":"Murakami Y, Uemura K, Sudo T et al (2009) Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 250(6):950\u2013956","journal-title":"Ann Surg"},{"issue":"5","key":"2642_CR16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00280-011-1805-7","volume":"69","author":"T Takahara","year":"2012","unstructured":"Takahara T, Nitta H, Hasegawa Y et al (2012) A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures. Cancer Chemother Pharmacol 69(5):1127\u20131133","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2642_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00280-014-2543-4","volume":"74","author":"S Kobayashi","year":"2014","unstructured":"Kobayashi S, Nagano H, Sakai D et al (2014) Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemother Pharmacol 74(4):699\u2013709","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"2642_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143072","volume":"10","author":"Y Fujiwara","year":"2015","unstructured":"Fujiwara Y, Kobayashi S, Nagano H et al (2015) Pharmacokinetic study of adjuvant gemcitabine therapy for biliary tract cancer following major hepatectomy (KHBO1101). PLoS ONE 10(12):e0143072","journal-title":"PLoS ONE"},{"issue":"2","key":"2642_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/SLA.0000000000002865","volume":"270","author":"S Kobayashi","year":"2019","unstructured":"Kobayashi S, Nagano H, Tomokuni A et al (2019) A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208): kansai hepato-biliary oncology group. Ann Surg 270(2):230\u2013237","journal-title":"Ann Surg"},{"issue":"12","key":"2642_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238568","volume":"15","author":"DJ Mole","year":"2020","unstructured":"Mole DJ, Fallowfield JA, Sherif AE et al (2020) Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer. PloS One 15(12):e0238568","journal-title":"PloS One"},{"issue":"6","key":"2642_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/BF02469796","volume":"14","author":"H Kohno","year":"1984","unstructured":"Kohno H, Inokuchi K (1984) Effects of postoperative adjuvant chemotherapy on liver regeneration in partially hepatectomized rats. Jpn J Surg 14(6):515\u2013523","journal-title":"Jpn J Surg"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02642-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02642-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02642-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T18:02:37Z","timestamp":1736013757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02642-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2642"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02642-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.M. reports research Funding from Eisai, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, J-Pharma, AstraZeneca, Merck biopharma, Daiichi Sankyo, Boehringer Ingelheim, and honoraria from Novartis, Yakult Honsha, Teijin Pahrma, Eisai, MSD, AstraZeneka, SERVIER, Boehringer Ingelheim, Taiho. J.M.reports Employment\/Leadership position\/Advisory role from Phizer and honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, AstraZeneca. S.K. reports research funding from Bayer, Boston Scientific, Chugai Pharmaceutical, Eisai, Eli Lilly Japan, Takeda, Taiho Pharmaceutical, Yakult Honsha. H.I reports fees for promotional materials from Medico\u2019s Hirata, and honoraria from Boston Scientific, Kaneka Medix, Medico\u2019s Hirata, SB KAWASUMI LABORATORIES, AstraZeneca. H.K. reports grants from BMS K.K., ONO Pharmaceutical, Eli Lilly Japan, MSD K.K., and Daiichi Sankyo, and honoraria from Bristol-Myers Squibb, Eli Lilly Japan, MSD K.K., Ono Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, Merck Biopharma, Takeda Pharmaceutical, Yakult Pharmaceutical Industry, Teijin Pharma, Taiho Pharmaceutical, Otsuka Pharmaceutical, Nippon Kayaku, and GlaxoSmithKline. M.I. reports Research Funding from AstraZeneca, Boehringer Ingelheim GmbH, Eisai, J-pharma, Merk biopharma, Ono Pharmaceutical, Eli Lilly Japan, and honoraria from AstraZeneca, Guardant Health Japan, Incyte, Taiho Pharmaceutical. N.M. reports research funding from Novartis, MSD, Incyte, Ono Pharmaceutical, Seagen, Pfizer, Boehringer Ingelheim, AstraZeneca and honoraria from Yakult Honsha, AstraZeneca, Novartis, FUJIFILM Toyama Chemical, MSD, Taiho Pharmaceutical, Boehringer Ingelheim. F.J. reports Research funding from MSD, J-Pharma, Delta-fly-Phrama, Taiho Pharmaceutical, Eisai, Ono Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Yakult Honsha and honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, Eisai, Incyte Biosiciences, Eli Lilly Japan, Fuji Film, AstraZeneca, Yakult Honsha. U.M. reports research funding from Taiho Pharmaceutical, AstraZeneca, MSD, Nihon Servier, Ono Pharmaceutical, Incyte Biosciences Japan GK, Chugai Pharmaceutical, Boehringer Ingelheim GmbH, J-pharma, Eisai, Novartis Pharma K.K, Astellas, J-pharma, Delta-fly-Phrama, Novocure GmbH, and Chiome Bioscience Inc. and honoraria from Taiho Pharmaceutical, AstraZeneca, K.K, Yakult Honsha, MSD K.K, Nihon Servier, Ono Pharmaceutical, Incyte Biosciences Japan GK, Chugai Pharmaceutical, Boehringer Ingelheim GmbH, J-pharma, Daiichi Sankyo, Eisai, Takeda Pharmaceutical, Novartis Pharma K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}